Changes in the diversity of local cervical bacteria in women with cervical cancer receiving antineoplastic treatment

Gauddy Lizeth Manzanares-Leal¹, Jaime Coronel-Martínez², Miguel Rodríguez-Morales²³, Lilia Patricia Bustamante-Montes⁴, Horacio Sandoval-Trujillo⁵, Ninfa Ramírez-Durán¹

¹Laboratory of Medical and Environmental Microbiology, Faculty of Medicine, Autonomous University of the State of Mexico, Toluca, Mexico, ²Clinical Research Division, National Institute of Cancerology, Mexico City, Mexico, ³Laboratory of Molecular Microbiology, National School of Biological Sciences, National Polytechnic Institute, Mexico City, Mexico, ⁴Dean’s Office of Health Sciences, Autonomous University of Guadalajara, Guadalajara, Mexico, ⁵Department of Biological Systems, Metropolitan Autonomous University-Xochimilco, Mexico City, Mexico

Some studies have published the impact of intestinal commensal bacterial species on the metabolism, efficacy, and toxicity of chemotherapeutic drugs, showing that the microbiota regulates the response to different types of cancer chemotherapy by affecting their mechanism of action and toxicity.[⁵⁻⁷]

The knowledge of the impact of the bacterial microbiota in the treatment of gastrointestinal cancer is widely studied. However, there is still a deficiency in the analysis of the impact of bacterial microbiota on...
showed that cervical microbiota
The public
This
[9,10]
radiotherapy from external beam to the whole pelvis and
in menopause (older than 45 years). All had as a treatment
included.
A total of 68 untreated women who were recently diagnosed
A descriptive, longitudinal, prospective study was carried out.
Study design and population
A descriptive, longitudinal, prospective study was carried out.

Study design and population
A descriptive, longitudinal, prospective study was carried out.

Characteristics of the study group
A questionnaire was applied to obtain sociodemographic and gynecological-obstetric data. The symptoms reported
by the patients at the end of each treatment, including pruritus, abnormal vaginal discharge, foul-smelling discharge, colored discharge, pelvic pain, dysuria, and tenesmus, were obtained from the clinical histories. In the same way, the data related to the disease and the administration of the treatment were obtained.

Antineoplastic treatment
Total external radiotherapy was applied to the pelvis with doses of 45–50.4 Gy covering the uterus, parametrium, vagina, common iliac nodes, internal and external, obturators, and presacrum. Concomitant chemotherapy based on cisplatin was administered weekly 40 mg/m². Chemotherapy and radiotherapy treatment lasted for 5 weeks.

Subsequently, brachytherapy was administered in one of the two available forms: low rate 2 Gy/h for a final dose of 30–55 Gy or high rate 12 Gy/h for a final dose of 30–55 Gy. The treatment with brachytherapy lasted 4 days.

Response to treatment was assessed 6 weeks after the completion of brachytherapy. The evaluation was based on changes in tumor size, observed by computed tomography scan and Response Evaluation Criteria In Solid Tumors criteria.[15] It was taken as a cure or complete response to the disappearance of all lesions and pathological nodes. It was taken as a persistent disease when the criteria for complete response were not met.[15]

If the disease persisted, patients took 8 weeks off before starting second-line chemotherapy. For the cure response to treatment, patients took 12 weeks off as a control period before being discharged.

Sampling
From each of the participants, four samples of cervicovaginal fluid were taken by swab throughout the antineoplastic treatment, using the following scheme:
- Initial assessment (IA): The initial sample was taken at the time of establishing the diagnosis of the presence of locally advanced CC.
• Postchemotherapy and radiotherapy assessment (P-QRT): The second sample was taken at the end of the concomitant chemotherapy and radiotherapy treatment
• Postbrachytherapy assessment (P-BT): The third sample was taken at the end of the brachytherapy treatment
• Final assessment (FA): The fourth sample was taken after the rest period before second-line chemotherapy or after the period of monitoring before discharge, as appropriate.

Sample processing
The procedures for microbiological analysis from sample processing to genetic identification were modified from previous publications and are described below.[16‑19] Under sterile conditions, the fibers were separated from the swab, placed in a 2.0 ml Eppendorf tube; 1 ml of saline was added and centrifuged at 14,000 rpm for 15 min. The remaining suspension was used to isolate bacteria.

Culture and isolation media
An aliquot of 200 μl of the suspension obtained from the sample was inoculated on a brain heart infusion (BHI; Becton Dickinson, Cat. No. 214700) agar plate, and 200 μl was inoculated in a Petri dish with blood agar (Becton Dickinson, Cat. No. 220150). The plates were incubated at 37°C for 48 h under aerobic conditions. Subsequently, the predominant colonies were isolated and purified.

Extraction of DNA
Pure cultures growing for 48 h at 37°C on IHB agar were used to obtain the biomass. The biomass was recovered by centrifugation, and DNA extraction was carried out using the Promega Wizard® genomic kit (Cat. No. A1120) according to the manufacturer’s instructions.

Amplification of the 16S ribosomal RNA gene
The 16S ribosomal RNA (rRNA) gene was amplified by polymerase chain reaction (PCR) using the obtained DNA and Tag DNA polymerase (MyTaq; Bioline, Cat. No. BIO-21105). The following universal primers were used:
• 27f: 5’-AGAGTTTGATCMTGGCTCAG-3’
• 1492r, 5’-TACGGYTACCTTGTTACGACTT-3’.

The following thermal cycling conditions were used for the amplification of the gene: initial denaturation at 94°C for 5 min, followed by 29 cycles of denaturation at 94°C for 1 min, annealing at 59°C for 30 s, and extension at 72°C for 1 min. The final extension was carried out for 10 min at 72°C.

The amplified fragments were separated by 1% agarose gel electrophoresis (CondaPronadisa, Cat. No. 8100.10) in TAE buffer (Invitrogen, Cat. No. 24710-030) at 120 V for 40 min and then stained with ethidium bromide (Sigma, Cat. No. E7637-1G).

Ribotyping of 16S ribosomal RNA by polymerase chain reaction-restriction fragment length polymorphism
In a sterile Eppendorf tube, 10 μl of a 16S rRNA amplificon was digested with the MspI enzyme (Promega, Cat. No. R6401) according to the manufacturer’s specifications. The same procedure was performed with the RsaI enzyme (Promega, Cat. No. R6371).

The restriction products were separated by electrophoresis in a 1.5% agarose gel (CondaPronadisa, Cat. No. 8100.10) in TAE buffer (Invitrogen, Cat. No. 24710-030) at 120 V for 80 min and stained with ethidium bromide (Sigma, Cat. No. E7637-1G), with 1-kb DNA ladder used as a molecular weight marker (Thermo Scientific, Cat. No. 5M0311).

The restriction patterns generated were analyzed by the number of bands and their sizes concerning the molecular weight marker. For grouping analysis, profiles containing at least two bands were included. A group of strains with identical restriction enzyme profiles was defined as a ribotype.

Identification of isolated strains
The selection of strains for genetic identification was based on the established ribotypes. The second round of PCR amplification of the 16S rRNA gene was performed, as described previously, using the DNA of each strain selected. The products of this amplification were purified using an Amicon Ultra® centrifugal filter unit (Millipore, Cat. No. UFC500308) and sent to a sequencing service (Macrogen, Rockville, MD, USA).

The obtained sequences were analyzed and edited using ChromasPro version 2.6.4 and BioEdit version 5.0.9. Consensus sequences were constructed and compared using the Basic Local Alignment Search Tool program, with sequences deposited in GenBank of the National Biotechnology Information Center as well as in the public database EzBiocloud. The obtained sequences were deposited in the GenBank of the National Center for Biotechnology Information with access numbers MH108987-MH109026, MK131292-MK131312.

Data analysis
The sociodemographic, gynecological-obstetric, the disease, and isolated strains characteristics were analyzed using descriptive statistics. We compared the proportion of women who presented the identified bacterial species, by stratified subgroup by fertile age and menopause, as well as the proportion of women who presented the species identified through antineoplastic treatments by Fisher’s
RESULTS

At the start of the study, 68 women with locally advanced CC were included. Throughout the study, there were losses to follow-up due to participants dropping out of the study, changing treatments, or death. The sample size at follow-up stages was $n = 68$ in IA, $n = 57$ in P-QRT, $n = 54$ in P-BT, and $n = 50$ in FA. The loss to follow-up was 26%.

Study group characteristics

The mean age of the patients was 45 years, and the mean education was six years; 64% had no family history of cancer, 55% were menopausal, 53% had more than three children, and 52% did not use contraception. According to the clinical stage of the disease, 15% of patients were in Stages IB2 to IIA2 (without parametrial invasion); the remaining 85% were in Stages IIB to IVA (with parametrial invasion). An epidermoid tumor was diagnosed in 89% of the participants, with an average size of 5 cm.

At the IA, 76% of the patients reported abnormal vaginal discharge with a foul odor and pruritus. At the P-QRT, 4% of the patients reported pruritus, 6% presented with abnormal vaginal discharge, 3% reported vaginal discharge with a foul odor and no changes in coloration, and 11% reported dysuria. During the P-BT, only one patient reported abnormal vaginal discharge with a foul odor. Finally, during FA, only one patient presented with dysuria, whereas the rest of the evaluated symptoms were absent in all the members of the study.

Treatment characteristics

For chemotherapy, 98% of patients received Cisplatin, 2% of patients received Vinorelbine because of their low tolerance to Cisplatin. The average dose of chemotherapy was 65.07 mg. The average dose of external radiation was 50.45 Gy. For brachytherapy, 68% of the patients received high rate brachytherapy, and 32% received low rate brachytherapy with total dose averages of 23 Gy and 35 Gy, respectively. Finally, 94% of the patients had a complete response to the treatment, and 6% had persistence of the disease.

Isolated strains and ribotyping by polymerase chain reaction-restriction fragment length polymorphism of 16S ribosomal RNA

From the initial samples, 116 strains were isolated, which were divided into 12 ribotypes. From postchemotherapy and radiotherapy, 71 strains were isolated, nine ribotypes were obtained. From the postbrachytherapy samples, 44 strains were isolated and grouped into nine ribotypes. Finally, from the samples collected at the FA, 66 strains were isolated, which were divided into 15 ribotypes.

Identification of isolated strains

The identification by sequencing of the 16S rRNA gene was performed on sixty strains. The consensus sequences obtained were between 1339 bp and 1421 bp, with percentages of similarity between 97% and 100%. The bacteria identified belonged to three phyla: Firmicutes, Proteobacteria, and Actinobacteria. A total of nine bacterial genera and 25 bacterial species were identified [Table 1].

Bacterial diversity

The most frequent bacterial species in the different treatment stages were in the IA Staphylococcus epidermidis, found in 51% of the women evaluated, and Corynebacterium amycolatum, present in 41% of the women evaluated. In the P-QRT evaluation, the most frequent bacterial species were S. epidermidis, found in 49% of the women evaluated, followed by Enterococcus faecalis, found in 40% of the women studied. In the P-BT evaluation, S. epidermidis was found in 20% of the women evaluated, followed by E. faecalis in 16%. In FA, 36% of the women presented S. epidermidis, and 16% presented Streptococcus agalactiae. The frequency of the remaining bacteria identified is presented in Table 1. There were statistically significant differences when comparing the proportion of women who presented the bacterial species found in the different stages of antineoplastic treatment [Table 1].

Bacterial diversity decreased as antineoplastic treatment progressed. In IA, 12 species were detected, representing 48% of all identified bacteria. In the P-QRT and P-BT assessments, nine of the 25 species identified in the study were found presenting 36% of the identified bacteria. Finally, in FA, 15 bacterial species were detected, representing 60% of all bacteria identified. When evaluating the differences in proportions in this area, no statistically significant data were found.

According to the clinical stage (evaluated before antineoplastic treatment), the stages without parametric invasion (IB2, IIA, IIA1, and IIA2) presented eight species out of the 12 identified in the initial assessment (IA): S. epidermidis, C. amycolatum, E. faecalis, Bacillus safensis, Lactobacillus rhamnosus, Escherichia fergusonii, Corynebacterium jeikeium and, Bacillus malikii. That is, 66% of the total number of species identified at that stage. The parametric invasion stages (IB, IIIA, IIIB and, IVA) presented the 12 species identified (100%): S. epidermidis, C. amycolatum, E. faecalis, E. fergusonii, S. agalactiae, C. jeikeium, B. safensis, Streptococcus urinalis, L. rhamnosus, B. malikii, Escherichia coli, and Corynebacterium striatum. Statistically significant differences were found in the presence of
S. epidermidis (P < 0.01), which occurred in 100% of the women with invasive parametric cancer and only 44% of women with non-parametric invasive cancer.

There were no statistically significant differences when evaluating differences in high rate versus low rate brachytherapy. There were no statistically significant differences in bacterial diversity when stratified by reproductive age and menopause or by chemotherapeutic agents administered.

**DISCUSSION**

The present report shows an analysis of the changes in the cervicovaginal bacterial composition evaluating the local species present. Only two reports about cervicovaginal microbiota and its changes under antineoplastic treatment have been published at this time. Mubangizi et al. determined the aerobic cervical bacteria prevalent in patients with advanced CC before and after external beam radiotherapy.

On the other hand, Tsakmaklis et al. in 2020, evaluated by molecular methods, quantitative and qualitative changes in cervical microbiota in 8 patients undergoing chemotherapy and radiotherapy. In this study, the authors reported a considerable reduction in cervical bacterial load after chemotherapy and radiotherapy. The quantitative changes are of great importance and provide new knowledge on the subject; however, they do not report changes in the composition of the microbiota evaluated.

Our study complements the little evidence that has been described to date. We evaluated a significant number of women (n = 68). Changes were observed in the different stages of locally advanced cancer, indicating that, when the cancer is established, the more advanced stages present a higher number of local bacterial species. This observation is...
consistent with the findings of Tango et al.,[21] who concluded that the variation in diversity might be associated with atypical health conditions. The greater diversity found may show a higher probability that the bacterial community present is not healthy. Kwasniowski et al.[22] suggest that there may be an association between HPV infection, a decrease in the abundance of Lactobacillus species, and an increase in other bacterial species.

The changes in bacterial composition were analyzed at four stages of treatment, in contrast to what was reported by Tsakmaklis et al.[11] and Mubangizi et al.[20] Our results show that chemotherapy and brachytherapy decrease local bacterial diversity, in contrast to previous reports. We also show that diversity increases again over time, after the completion of the antineoplastic therapy.

Previous data about the cervical bacterial community of healthy women generally define it as a community dominated by lactobacilli. However, it has now also been reported that a high percentage of Latina women are characterized by a combination of nonlactobacillar communities.[23,24] In our study, the bacterial communities evaluated throughout the treatment showed only the presence of one species of Lactobacillus. This finding does not prove that the Lactobacillus genus is not present in the population group evaluated. However, our results could show that there is a numerical prevalence of the other bacterial species, forming a community with a low lactobacillar presence, which differs widely from the concept of a healthy cervical bacterial community. These results are in line with what has been described by Di Paola et al.[25]

We also showed that, when patients received chemotherapy and radiotherapy, they had a different bacterial community than that found when receiving brachytherapy. Finally, the bacterial community found at the beginning of the study was also different from the bacterial community found at the end of the treatments.

Within the limitations of the study, we can consider that only the culture-dependent aerobic bacterial community was evaluated. The analysis of the culture-dependent anaerobic bacterial community is proposed, as well as the analysis of the nonculture-dependent bacterial community. A control group with healthy women was not evaluated either. The aim of the study was not to compare women with CC and women without CC but to compare the change in microbiota in the presence of antineoplastic treatment. For this reason, this study was established longitudinally, so the initial measurement worked as a control group to evaluate the bacterial community present before the treatments. Future studies may consider the option of including a healthy control group.

CONCLUSION

Our results support the hypothesis that antineoplastic treatments change the composition of the cervicovaginal microbiota. With this study, it is possible to raise new hypotheses and proposals to evaluate if these changes influence the response to treatment and the improvement of the quality of life of patients with CC.

Acknowledgments

We recognize the Consejo Nacional de Ciencia y Tecnología de México (CONACYT) for this work, which derives from the doctoral thesis carried out within the framework of the National Postgraduate Quality Program (PNPC-CONACYT).

Financial support and sponsorship

The authors acknowledge financial assistance from the Secretary of Research and Advanced Studies of the Universidad Autónoma del Estado de México 4350/2017/CI, Changes in cervicovaginal microbiota of women with cervical cancer during antineoplastic treatment, and the network “Microbiología y Química en las Ciencias de la Salud” 1039/2014RIF.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Pereira-Marques J, Ferreira RM, Pinto-Ribeiro I, Figueiredo C. Helicobacter pylori infection, the gastric microbiome and gastric cancer. Adv Exp Med Biol 2019;1149:195-210.
2. Sukri A, Hanaiah A, Mohamad Zin N, Kosai NR. Epidemiology and role of Helicobacter pylori virulence factors in gastric cancer carcinogenesis. APMIS 2020;128:150-61.
3. Baj J, Korona-Glowniak I, Forma A, Maani A, Sitarz E, Rahnama-Hezavah M, et al. Mechanisms of the epithelial-mesenchymal transition and tumor microenvironment in Helicobacter pylori – Induced gastric cancer. Cells 2020;9:1055.
4. Gettings-Behncke C, Coleman HG, Jordao HW, Longley DB, Crawford N, Murray LJ, et al. Fusobacterium nucleatum in the colorectum and its association with cancer risk and survival: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2020;29:539-48.
5. Garrett WS. Cancer and the microbiota. Science 2015;348:880-6.
6. Roy S, Trinchieri G. Microbiota: A key orchestrator of cancer therapy. Nat Rev Cancer 2017;17:271-85.
7. Goubet AG, Daillère R, Routy B, Derosa L, M Roberti P, Zitvogel L. The impact of the intestinal microbiota in therapeutic responses against cancer. C R Biol 2018;341:284-9.
8. Isla-Ortiz D, Palomares-Castillo E, Mille-Loera JE, Ramírez-Calderón N, Mohar-Bétancourt A, Meneses-García AA, et al. Cervical cancer in young women: Do they have a worse prognosis? A retrospective cohort analysis in a population of Mexico. Oncologist 2020;25:e1363-71.
9. Chopra S, Gupta M, Mathew A, Mahantshetty U, Engineer R, Lavanya G, et al. Locally advanced cervical cancer: A study of 5-year outcomes. Indian J Cancer 2018;55:45-9.
7

10. Tangjitgamol S, Katanyoo K, Laopaiboon M, Lumbiganon P, Manusirivithayas, Supawattanabodee B. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer. Cochrane Database Syst Rev 2014;12:CD010401.

11. Tsakmaklis A, Vehreschild M, Farowski F, Trommer M, Kohler C, Herter J, et al. Changes in the cervical microbiota of cervical cancer patients after primary radio-chemotherapy. Int J Gynecol Cancer 2020;30:1326-30.

12. Pecorelli S, Zigianni L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 2009;105:107-8.

13. Coronel JA, Cetina L, Cantú D, Cerezo O, Hernández CS, Rivera L, et al. A randomized comparison of cisplatin and oral vinorelbine as radiosensitizers in aged or comorbid locally advanced cervical cancer patients. Int J Gynecol Cancer 2013;23:884-9.

14. Dueñas-González A, Cetina L, Coronel J, Martínez-Baños D. Pharmacotherapy options for locally advanced and advanced cervical cancer. Drugs 2010;70:403-32.

15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.

16. Srinivasan S, Munch MM, Sizova MV, Fiedler TL, Kohler CM, Hoffman NG, et al. More easily cultivated than identified: Classical isolation with molecular identification of vaginal bacteria. J Infect Dis 2016;214 Suppl 1:S21-8.

17. MacPhee RA, Miller WL, Gloor GB, McCormick JK, Hammond JA, Burton JP, et al. Influence of the vaginal microbiota on toxic shock syndrome toxin 1 production by Staphylococcus aureus. Appl Environ Microbiol 2013;79:1835-42.

18. Zhou X, Hansmann MA, Davis CC, Suzuki H, Brown CJ, Schütte U, et al. The vaginal bacterial communities of Japanese women resemble those of women in other racial groups. FEMS Immunol Med Microbiol 2010;58:169-81.

19. Rohit A, Maiti B, Shenoy S, Karunasagar I. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for rapid diagnosis of neonatal sepsis. Indian J Med Res 2016;143:72-8.

20. Mubangizi L, Namusoke F, Mutyaba T. Aerobic cervical bacteriology and antibiotic sensitivity patterns in patients with advanced cervical cancer before and after radiotherapy at a national referral hospital in Uganda. Int J Gynaecol Obstet 2014;126:37-40.

21. Tango CN, Seo SS, Kwon M, Lee DO, Chang HK, Kim MK. Taxonomic and functional differences in cervical microbiome associated with cervical cancer development. Sci Rep 2020;10:9720.

22. Kwasniewski W, Wolun-Cholewa M, Kotarski J, Warchol W, Kuzma D, Kwasniewska A, et al. Microbiota dysbiosis is associated with HPV-induced cervical carcinogenesis. Oncol Lett 2018;16:7035-47.

23. Kalia N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: A critical review. Ann Clin Microbiol Antimicrob 2020;19:5.

24. Curty G, de Carvalho PS, Soares MA. The role of the cervicovaginal microbiome on the genesis and as a biomarker of premalignant cervical intraepithelial neoplasia and invasive cervical cancer. Int J Mol Sci 2019;21:222.

25. Di Paola M, Sani C, Clemente AM, Iossa E, Castronovo G, et al. Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection. Sci Rep 2017;7:10200.